Trials / Withdrawn
WithdrawnNCT02864628
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
A Partially Randomized, Partly Placebo Controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN® RSV Vaccine After Intranasal and Intramuscular Administration
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Accepted
Summary
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-BN-RSV | MVA-mBN294B |
| OTHER | Placebo | Tris Buffered Saline |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-10-27
- Completion
- 2017-10-27
- First posted
- 2016-08-12
- Last updated
- 2018-08-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02864628. Inclusion in this directory is not an endorsement.